Natural killer cells, macrophages and dendritic cells as innate immune therapies for blood cancers
Annals of Hematology · 02.03.2026 · 105 (4)
DOI: 10.1007/s00277-026-06872-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Hematology, online erschienen am 02.03.2026. Verfasst von Ghaleb Oriquat und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. Hauptthemen laut MEDLINE: Killer Cells, Natural, Dendritic Cells, Macrophages, Immunity, Innate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Innate immune cells are emerging as powerful allies in the fight against blood cancers. Natural Killer (NK) cells, macrophages, and dendritic cells (DCs)—once viewed mainly as supporting players—are now at the forefront of next-generation immunotherapies, owing to their rapid, antigen-independent tumor recognition and potent effector functions. This review highlights their distinct anti-tumor roles: NK cells’ cytotoxicity and “missing-self” recognition, the dual and adaptable nature of macrophages in the tumor microenvironment (TME), and the antigen-presenting capabilities of DCs that bridge innate and adaptive immunity. We further examine transformative therapeutic strategies, including adoptive NK cell transfer, CAR-engineered NK cells (CAR-NK), CAR-macrophages (CAR-M), and DC vaccines, with a focus on clinical outcomes and safety—particularly the encouraging toxicity profile of CAR-NK cells. Despite these advances, major challenges persist, including limited persistence and homing of infused cells, TME-driven immunosuppression, and potential on-target/off-tumor effects. To overcome these barriers, synergistic approaches that integrate innate immune therapies with checkpoint inhibitors, conventional treatments, innovative engineering, and precise modulation of the TME will be essential. These strategies hold the promise of translating scientific breakthroughs into durable, safe, and widely accessible treatments for patients with hematological malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
- Department of Pharmacology and Toxicology, College of Pharmacy, Al Farahidi University, Baghdad, Iraq. waleedk.abdulsahib@uoalfarahidi.edu.iq.
- College of Pharmacy, Al-Turath University, Baghdad, Iraq.
- Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
- Department of Immunology, IMS and SUM Hospital, Siksha 'O' Anusandhan, Bhubaneswar, 751003, Odisha, India.
- Department of Biotechnology, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Zitieren
APA
Oriquat, G., Abdulsahib, W. K., Ismael, S. H., Roopashree, R., Patro, P. S., Nellore, J., Mukherjee, G., Chauhan, A. S., & Musayeva, S. (2026). Natural killer cells, macrophages and dendritic cells as innate immune therapies for blood cancers. Annals of Hematology, 105(4). https://doi.org/10.1007/s00277-026-06872-x
Vancouver
Oriquat G, Abdulsahib WK, Ismael SH, Roopashree R, Patro PS, Nellore J, et al. Natural killer cells, macrophages and dendritic cells as innate immune therapies for blood cancers. Annals of Hematology. 2026;105(4). doi:10.1007/s00277-026-06872-x
BibTeX
@article{Oriquat2026,
author = {Oriquat, Ghaleb and Abdulsahib, Waleed K and Ismael, Sajida Hussein and Roopashree, R and Patro, Pradeepta Sekhar and Nellore, Jayshree and Mukherjee, Gunjan and Chauhan, Ashish Singh and Musayeva, Saodat},
title = {Natural killer cells, macrophages and dendritic cells as innate immune therapies for blood cancers},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {4},
doi = {10.1007/s00277-026-06872-x}
}
EUVIMED